Related Experiment Video

Updated: Sep 3, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K

[A practical approach to guideline-directed pharmacological treatment for heart failure with reduced ejection

Samira Soltani, Michael Böhm, Norbert Frey

    Deutsche Medizinische Wochenschrift (1946)
    |July 22, 2022
    PubMed

    Insights

    The 2021 ESC guidelines recommend four key drug classes for heart failure with reduced ejection fraction (HFrEF). This guide supports physicians in safely implementing these essential mortality-lowering treatments for HFrEF patients.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • The 2021 European Society of Cardiology (ESC) guidelines emphasize early treatment for heart failure with reduced ejection fraction (HFrEF).
    • Four drug classes are recommended to lower mortality in HFrEF patients.

    Purpose of the Study:

    • To provide a practical guide for physicians on implementing guideline-directed medical therapy for HFrEF.
    • To support the safe and effective use of four key drug classes in HFrEF management.

    Main Methods:

    • The article summarizes the 2021 ESC guidelines for HFrEF pharmacotherapy.
    • It focuses on the practical application of four mortality-lowering drug classes.

    Main Results:

    • Early implementation of ACEi/ARNI, BB, MRA, and SGLT2i is recommended for HFrEF.
    • Physicians are supported with practical information for safe and effective treatment initiation.

    Conclusions:

    • Adherence to the 2021 ESC guidelines ensures optimal HFrEF management.
    • This compendium facilitates the practical application of evidence-based pharmacotherapy for improved patient outcomes.

    More Related Videos

    Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

    Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

    Published on: February 13, 2021

    6.6K
    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

    Published on: July 7, 2016

    8.4K

    Related Concept Videos

    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    23
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    497
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    25
    Heart Failure IV: Classification and Diagnostic Evaluation01:30

    Heart Failure IV: Classification and Diagnostic Evaluation

    Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
    27
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
    424
    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
    30